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Type 2 Diabetes Mellitus and Its Association with the Risk of 
Pancreatic Carcinogenesis: A Review
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Department of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University 
of Gondar, Gondar, Ethiopia 
The prevalence of diabetes mellitus (DM) and associated diseases such as cancers are substantially increasing worldwide. 
About 80% of the patients with pancreatic cancer have glucose metabolism alterations. This suggests an association between 
type 2 DM and pancreatic cancer risk and progression. There are hypotheses that show metabolic links between the diseases, 
due to insulin resistance, hyperglycemia, hyperinsulinemia, low grade chronic inflammation, and alteration in the insulin-insulin-like 
growth factor axis. The use of diabetes medications can influence the extent of carcinogenesis of the pancreas. This study 
briefly reviews recent literature on investigation of metabolic link of type 2 DM, risk of carcinogenesis of the pancreas and 
their association, as well as the current understanding of metabolic pathways implicated in metabolism and cellular growth. 
The main finding of this review, although there are discrepancies, is that according to most research long-term DM does 
not raise the risk of pancreatic cancer. The longest duration of DM may reflect hypoinsulinemia due to treatment for hyperglycemia, 
but recent onset diabetes was associated with increased risk for pancreatic cancer due to hyperinsulinemia and hyperglycemia. 
In conclusion, the review demonstrates that type 2 DM and the duration of diabetes pose a risk for pancreatic carcinogenesis, 
and that there is biological link between the diseases. (Korean J Gastroenterol 2016;67:168-177)
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INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic disorders 
of multiple etiologies characterized by chronic hyperglycemia 
with disturbances of carbohydrate, fat and protein metabo-
lism resulting from defects in insulin secretion, action, or 
both.1 Several pathogenic processes are involved in the de-
velopment of DM. These range from autoimmune destruction 
of the cells of the pancreas with consequent insulin deficiency 
to abnormalities that result in resistance to insulin action. 
Deficient insulin action results from inadequate insulin secre-
tion and diminished tissue responses to insulin at one or more 
points in the complex pathways of hormone action.1
Type 2 diabetes mellitus (T2DM) consists of an array of dys-
functions characterized by hyperglycemia and resulting from 
the combination of resistance to insulin action, inadequate 
insulin secretion, and excessive or inappropriate glucagon 
secretion. It comprises over 90% of all DM cases and is usu-
ally diagnosed after 40 years of age, although recently much 
younger cases are being reported. Poorly controlled T2DM is 
associated with an array of microvascular and macro-
vascular complications.2,3
Longitudinal and cross-sectional studies have demon-
strated that the earliest detectable abnormality in T2DM is 
an impairment of the body’s ability to respond to insulin. 
Genetic susceptibility and environmental factors are the 
most likely triggers of T2DM.4,5 
The main function of the pancreas is to produce endocrine 
hormones and digestive enzymes that help break down car-
bohydrates, fats and proteins. The link between diabetes and 
cancer exists because T2DM is associated with increased in-
sulin production; insulin causes the growth of cells and the 
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proliferation of blood vessels in the pancreas that generates 
a hospitable environment for tumor formation.6 
Pancreatic cancer (PC) is a malignant tumor of the pan-
creas, and one of the most tragic and least understood of can-
cers, affecting the cells that produce insulin and glucagon.6 
The majority of PC originates from the ductal epithelial cells 
of the exocrine portion of the pancreas. There is extensive in-
teraction between the endocrine and exocrine portions of the 
pancreas during pancreatic carcinogenesis.6 It is charac-
terized by an increased incidence in Western industrialized 
countries, an extremely poor median survival of four to six 
months after diagnosis and with an overall five-year survival 
of less than 4%.7 
The incidence and number of deaths caused by PC have 
been gradually rising, although incidence and mortality of 
other common cancers have been declining.8 Inability to de-
tect PC at an early stage, its aggressiveness, and the lack of 
effective systemic therapy are responsible for the rapid death 
of PC patients.9 The poor outcome is a strong motivation for 
epidemiological research designed at identifying and re-
ducing risk factors for PC. Besides age and genetic risk fac-
tors, several lifestyle and environmental factors, such as 
smoking, obesity, low physical activity and alcohol con-
sumption are associated with PC.10 
T2DM is associated with PC, but it is unclear whether DM 
is a causal factor or the result of subclinical malignancy.11 
T2DM may directly promote the progression of PC by pancre-
atic duct enlargement and hypertension, as well as increased 
tumor size. Up to 80% of PC patients are either hyperglycemic 
or diabetic, both of which can be detected in the pre-sympto-
matic phase. Hyperglycemia and glucose tolerance aberrations 
may be the first easily testable clinical manifestation of DM.12
At question is whether coincidence of diabetes and the risk 
of certain cancers is largely due to shared risk factors, or 
whether diabetes itself, and the specific metabolic disorders 
typical of diabetes, increase the risk of some types of cancer.13 
The development of DM within a few years of a PC diagnosis 
suggests an effect of the tumor, whereas DM of longer dura-
tion is more likely to contribute to the development of cancer.14 
T2DM and PC are linked, but researchers have found it diffi-
cult to determine which influences the other.15 Based on the 
findings from several retrospective and prospective ob-
servational studies, T2DM and glucose intolerance are fairly 
reliable, albeit somewhat debatable, risk factors for PC.16-19
A helpful perspective can be obtained by examining re-
search focusing on T2DM in the setting of PC to gain further 
understanding of the link between T2DM and PC. In develop-
ing countries, especially in Ethiopia, T2DM patients are not 
screened for PC, although glycemic control is used for man-
agement of DM to control micro and macro vascular compli-
cation. Therefore, this review examines the metabolic link 
and association between T2DM and the risk of pancreatic 
carcinogenesis, and provides the most reliable information 
on the magnitude of association.
MAIN SUBJECTS
1. Mechanism of T2DM-associated pancreatic carcino-
genesis
Carcinogenesis is a multifaceted process whereby normal 
cells go through multiple genetic hits before the full neoplastic 
phenotype of growth, invasion, and metastasis occurs. This 
process of malignant transformation can be divided into mul-
tiple steps: initiation, promotion and progression.20 Factors 
that affect one or more steps of this pathway could be asso-
ciated with cancer incidence or mortality. The mechanism of 
the association between DM and PC is mysterious but most 
hypothesized mechanisms underlying the association be-
tween T2DM and PC include hyperinsulinemia, insulin resist-
ance (IR), elevated levels of circulating insulin-like growth fac-
tors (IGFs), hyperglycemia and chronic inflammation that in-
fluences tumor growth.20
The pancreas is exposed to high concentrations of endoge-
nously produced insulin. The causal nature of the association 
with PC risk is complicated by the fact that abnormal glucose 
metabolism may be a consequence of PC. However, a positive 
association between T2DM and PC risk has been found when 
restricted to T2DM that precedes the diagnosis of PC by at 
least five years.21 
1) Hyperinsulinemia and insulin resistance
Recent epidemiological and clinical evidence points to a 
link between IR and PC. Increased risk of cancer among IR pa-
tients is explained in part by overproduction of reactive oxy-
gen species (ROS) that can damage DNA, contributing to mu-
tagenesis and carcinogenesis. On the other hand, it is possi-
ble that the abundance of inflammatory cells in adipose tis-
sue of obese and T2DM promotes systemic inflammation. 
Such adiposity is common with hyperinsulinemia and IR, 
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leading to a tumorigenic environment.22 Both insulin and 
IGF-1 have affinity for both the insulin receptor and IGF-1 re-
ceptor (IGF-1R) because of similar structural homology. 
However, it is important to recognize that insulin’s affinity for 
the insulin receptor is 1,000 fold greater than for IGF-1R.23 
Both IGF-1 and IGF-1R tend to have stronger mitogenic and 
anti-apoptotic effects, and the hyperinsulinemia that occurs 
in IR individuals may enhance this effect.20,23
IR status, characterized by hyperinsulinemia, is asso-
ciated with an increased risk for a number of malignancies, 
including carcinomas of the breast, prostate, colon, pan-
creas and kidney.18 The insulin cancer hypothesis proposes 
that chronic hyperinsulinemia reduces concentrations of 
IGF binding protein (IGFBP-1 and -2), leading to increased 
tissue levels of IGF-1, crucial in the development and pro-
gression of cancers.18 Hyperinsulinemia may also accelerate 
tumor growth indirectly through its effects on IGF-1. Cancer 
cells over-express insulin and IGF-1 receptors, and insulin re-
duces the hepatic production of IGFBP-1 and -2. This leads 
to increased levels of free circulating physiologically active 
IGF-1.24 This could act as a growth stimulus in cancer cells 
that express such receptors.24 Hyperinsulinemia stemming 
from IR may happen for many years before diabetes diag-
nosis, with widespread effects. Normally, when insulin binds 
to its receptors, it activates two pathways: the metabolic 
pathway and the mitogenic pathway.25
Insulin resistance hinders the metabolic pathway, which is 
the pathway that increases transport of glucose into cells, 
stimulates glycogen synthesis, and suppresses liver gluco-
neogenesis. In the absence of insulin’s normal postprandial 
inhibition activity lipolysis, circulating free fatty acid levels im-
portant to the pathogenesis of IR and liver triglyceride pro-
duction rise, which contributes to atherogenic dyslipidemia. 
In contrast, IR does not inhibit activation of the mitogenic 
pathway that promotes proliferation of normal and cancer-
ous cells.26 Chronic hyperinsulinemia results, leading to a 
chain of metabolic responses, including changes in IGFBP 
that result in increased tissue availability of both IGF-1 and 
-2.27 Insulin itself is a growth promoting hormone with mito-
genic (but not mutagenic) effects and diabetes associated 
cancer cells express insulin and IGF-1 receptors which play 
a key role in cell growth and differentiation.27,28
Experimental evidence on animal studies complemented 
by case studies in humans demonstrate the critical role of IGF 
in all stages of mammalian growth.29 IGFBP-1 is suppressed 
by insulin; this raises the levels of bioavailable IGF-1. Further-
more, insulin up-regulates the bioavailability of IGFs by re-
ducing hepatic production of IGFBP.30
The mitogenic and anti-apoptotic activities of IGF-1 are 
more potent than those of insulin and may act as growth stim-
uli in cells expressing insulin and the IGF-1R. IGF-1 and 
IGF-1R are highly expressed in PC cells. IGF-1-mediated sig-
naling transduction increases proliferation, invasion, and ex-
pression of angiogenesis mediators and decreases apopto-
sis in PC cells. IGF-1R mediated initiation of signal trans-
duction activates important intracellular signal pathways, in-
cluding the Ras/Raf/mitogen-activated protein kinase 
(MAPK) and phosphoinositide-3 kinase/Akt/(PI3K) mam-
malian target of rapamycin (mTOR) pathways.24
Furthermore, in IR states, T2DM causes impairment of 
downstream glucose transporter 4 (GLUT4) translocation by 
disruption of insulin receptor substrate-1 (IRS-1)-associated 
PI3K signaling in the metabolic pathway of insulin.31 Insulin, 
to a lesser degree than IGF-1, motivates cellular growth and 
protein synthesis through the protein kinase B (PKB) system 
and activation of mTOR.32 Abnormal IRS-1 phosphorylation 
from over activation of mTOR creates a negative feedback 
loop that attenuates the metabolic pathway in hyperinsuli-
nemia.24 IRS-2 expression by insulin phosphorylation leads 
to increased extracellular signal regulated kinase (ERK) acti-
vation; MAPK because the mitogen pathways mediated by 
mTOR and Ras remain intact.32 This drive towards the mi-
togen pathway with hyperinsulinemia leads to enhanced cell 
growth and survival. Therefore, the leading hypothesis for the 
relationship between T2DM and PC is that IR and con-
sequently hyperinsulinemia may promote tumor cell growth 
directly via insulin receptors33 or indirectly via the IGF-1R.34 
The shared metabolic factors underlying both T2DM and 
cancer, including visceral adiposity, inflammation, hyper-
glycemia, and hyperinsulinemia, lead to increased IRS, stim-
ulating the phosphorylation of Ras signaling proteins, and po-
tentially increasing tumor cell growth and proliferation. 
IRS-associated PI3K signaling is compromised by IR states, 
such as in T2DM, and downstream GLUT4 translocation is 
disrupted. This disruption drives PI3K signaling towards 
AKT/mTOR. AKT and mTOR can affect both the metabolic and 
mitogenic pathway, but because of the signaling dysfunction, 
AKT and mTOR are driven towards the mitogenic pathway.35
Biadgo B and Abebe M. Association between Type 2 DM and Pancreatic Carcinogenesis 171
Vol. 67 No. 4, April 2016
(1) Insulin-insulin like growth factor axis: Insulin and 
the IGF axis have a number of effects on cancer cells. When 
both the insulin and IGF receptors interact with their ligands, 
multiple signaling pathways are activated, leading to phos-
phorylation of adaptor proteins such as the IRS family. These 
signaling pathways may promote proliferation and may affect 
invasion, metastasis, and protection from apoptotic stimuli.36
Insulin and IGF receptors form a complex network of cell 
surface receptors; homodimers and heterodimers have 
been described, and all function to mediate insulin and IGF 
responses.24 The majority of cancer cells express insulin and 
IGF-1Rs; the A isoform of the insulin receptor is frequently 
expressed. The ‘A’ receptor isoform can encourage in-
sulin-mediated mitogenesis, even in cells deficient in 
IGF-1Rs.37 In addition to its metabolic functions, the insulin 
receptor is accomplished in stimulating cancer cell pro-
liferation and metastasis. Because most glucose uptake in 
cancer cells is constitutively high and independent of insulin 
binding to its receptor, the effects of insulin receptor activa-
tion on neoplastic cells may relate more to cell survival and 
mitogenesis than to enhanced glucose uptake.38
Multiple signaling pathways are activated after IGF-1Rs in-
teract with their ligands by phosphorylating adaptor proteins, 
most notably the IRS family. The initial kinase event is linked 
to downstream signaling pathways.36 Once activated these 
signaling pathways may stimulate multiple cancer pheno-
types including proliferation, protection from apoptotic stim-
uli, invasion, and metastasis, potentially enhancing the pro-
motion and progression of many types of cancer cells.36,39 It 
is also clear that during hyperglycemia, IGF may stimulate 
normal cells that are involved in cancer progression that al-
lows IGF-1 to stimulate vascular smooth muscle cell pro-
liferation and migration.39 Although this process has been 
linked to the pathophysiology of atherosclerosis, abnormal 
vascular growth is also a hallmark of cancer.40,23 
2) Hyperglycemia
Laboratory studies suggest that higher circulating glucose 
may support malignant cell growth.42 Biologically based 
mass spectrometry techniques document that proliferating 
tumor cells preferably use glucose to synthesize the ribose 
5-phosphate required for nucleic acid synthesis.43 
Prospective cohort and case-control studies show that hy-
perglycemia is associated with increased free radical for-
mation and may lead to the development of advanced glyca-
tion end products (AGEs) that can increase inflammation.43 
These studies also report the link between elevated hemo-
globin A1C and other measures of hyperglycemia with an in-
creased risk of colorectal, pancreatic, endometrial, and oth-
er cancers.10,43 ROS, produced due to activation of various 
metabolic pathways like polyol pathway, auto oxidation of glu-
cose, lipid peroxidation and Maillard’s reaction, appear to be 
linked to PC, suggested to be mitogenic and capable of stim-
ulating cell proliferation.44 Moreover, hyperglycemia IR, hy-
perinsulinemia and inflammation can cause DNA damage, 
boost the invasive and migratory activity of PC cells via hydro-
gen peroxide and the increased expression of urokinase plas-
minogen activator (uPA).45 Hyperglycemia can attenuate an-
tioxidant enzyme activity and in turn create a state of oxida-
tive stress.46 
3) Chronic inflammation
Inflammatory cytokines, ROS, and mediators of inflam-
matory pathways, such as cyclooxygenase-2 (COX-2) and nu-
clear factor kappa B (NFκB) are associated with oncogene ex-
pression, silencing of tumor suppressor genes, and affect the 
cell cycle, all of which may facilitate pancreatic carcino-
genesis.46,47 Chronic, low-grade inflammation can result 
from DNA damage and create an environment in which more 
damage occurs.48 
Adipose tissue is an active endocrine organ recognized as 
a low-grade inflammatory state in which overproduction of 
certain molecules, such as free fatty acids, interleukin-6, 
monocyte chemo attractant protein, plasminogen activator 
inhibitor 1 (PAI-1), adiponectin, leptin, and tumor necrosis 
factor alpha (TNF-) that might play an etiologic role in regu-
lating malignant transformation or cancer progression.49-51
Adiponectin increases fatty acids oxidation, which lowers 
circulating free fatty acids and prevents IR, and it exerts an 
anti-atherosclerotic effect, while augmenting endothelial ni-
trous oxide production and protecting the vasculature by re-
ducing platelet aggregation and vasodilation.52 Apart from 
causing metabolic dysfunction, adiponectin deficiency may 
also contribute to cardiovascular disease, IR, and a wide ar-
ray of cancers.52 
The decrement of adiponectin precedes the development 
of IR and myocardial infarction in humans; low levels of adipo-
nectin are likely to be a causal component of those 
disorders.53 A study in Pima Indians shows individuals with 
high levels of adiponectin were less likely to develop T2DM, 
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suggesting that high adiponectin concentration has anti-in-
flammatory, anti-apoptotic and pro-angiogenic activities, 
protective factor against development of T2DM.54,55
2. Epidemiological evidences for type 2 diabetes mel-
litus and pancreatic cancer
The prevalence of DM has increased dramatically around 
the globe and is rapidly becoming an overwhelming public 
health problem in developing countries.56 An estimated 366 
million people were living with DM in 2011. The number is ex-
pected to grow to 552 million by 2030, and the largest age 
group currently affected by DM is between 40-59 years. The 
African continent is expected to experience the highest in-
crease in the coming years with estimated increase in preva-
lence rates of 98% for sub-Saharan Africa, and 94% for North 
Africa and the Middle East and 20% increase in developed 
countries.57,58
A 2010 consensus report from a panel of experts chosen 
jointly by the American Diabetes Association and American 
Cancer Society suggested that people with T2DM are at an 
increased risk for many types of cancer.16,50,59-61 Evidence 
from observational studies suggests that some medications 
used to treat hyperglycemia are associated with changed risk 
of PC.50 For more than 50 years, clinicians have reported the 
occurrence of patients with concurrent DM and PC.62 
However, research as early as 1959 stated that although 
studies examining the association between DM and cancer 
were conducted over several years, there was no conclusive 
evidence of a positive association. Subsequently, an associa-
tion between the diseases was identified in the 1960s in pop-
ulation based studies.63
PC is the fourth or fifth most common cause of cancer 
deaths in economically developed countries.64-66 In the Euro-
pean Union, 29,600 deaths in men and 29,900 deaths in 
women due to PC were estimated for 2004.65 The bilateral 
causality between the diseases has been widely docu-
mented.13,67 
Epidemiological studies clearly indicate that the risk of PC 
is increased in DM patients, but most studies focus on T2DM. 
The recent increase in the prevalence of T2DM is thought to 
have contributed to a parallel rise in the incidence of PC.68 
Worldwide, the prevalence of cancer is difficult to establish 
because many areas do not have cancer registries, but in 
2008 there were an estimated 12.4 million new cancer cases 
diagnosed.69 The most commonly diagnosed cancers were 
those of the lung, breast, and colorectal, whereas the most 
common causes of cancer deaths were lung, stomach, pan-
creas and liver cancer.69 It has long been known that PC is as-
sociated with DM, and recent studies have revealed that 
about 85% of patients diagnosed with PC have impaired glu-
cose tolerance.70
3. The association between type 2 diabetes mellitus 
and the risk of developing pancreatic cancer
Assessing the relationship between DM and the risk of PC 
poses challenges. Some epidemiological studies observe a 
relationship between the presence of T2DM and the develop-
ment of PC. There are a number of potentially plausible ex-
planations for the observed association between T2DM and 
PC, including shared risk factors, and metabolic derange-
ments such as the metabolic syndrome. IR and hyper-
insulinemia are hallmarks of cancers associated with these 
conditions.51,71 Although there are proposed mechanisms of 
diabetes related pancreatic carcinogenesis, epidemiological 
studies clearly indicate that DM is positively associated with 
an increased risk of PC.72,73
A large prospective study in the United States (US) followed 
a cohort of 467,922 men and 588,321 women for 16 years 
who had no reported history of cancer. The results showed 
that independent of a high body mass, T2DM acts as a pre-
dictor of mortality from cancer of the colon, pancreas, female 
breast, male liver and bladder.74 Even though there is a strong 
association between PC and DM, the temporal sequence is 
unclear. However, 1% of newly diagnosed DM patients great-
er than 50 years of age will contract PC within three years.75
A population based retrospective cohort study in China 
showed that increased risk of developing cancer was found 
in both male and female T2DM patients with a standardized 
incidence ratio (SIR) of 1.331 (95% CI, 1.143-1.518) and 
1.737 (1.478-1.997), respectively. As for different cancer 
subtypes, both male and female T2DM patients had a sig-
nificantly increased risk of PC with the SIRs of 2.973 
(1.73-4.21) and 2.687 (1.445-3.928), respectively. These 
findings indicated that patients with T2DM have an in-
creased risk of developing PC.76
A systematic review of the association between DM and PC 
was undertaken by searching electronic databases and jour-
nal references from 1973 to 2013 in Australia. A total of 88 
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independent studies, including 50 cohort and 39 case con-
trol studies, were examined. The overall summary RR was 
1.97 (95% CI, 1.78-2.18) with marked heterogeneity that 
could not be clearly attributed to any subgroup analyses. The 
risk of PC was greatest early after the diagnosis of DM and 
remained elevated long after the diagnosis. The individual 
level RR ranged from 6.69 at less than 1 year to 1.36 at 10 
years.77,78
A prospective study found an association between a his-
tory of DM and subsequent risk of cancer in Japan. In men, 
a 27% increase in the risk of total cancer incidence (hazard 
ratio [HR] 1.27, 95% CI 1.14-1.42; and HR 1.85, 95% CI 
1.07-3.20)78 was seen for PC alone with a history of DM. A 
study done by the Alpha-Tocopherol Beta-Carotene Cancer 
prevention study shows smoking had significant (two-fold) 
contribution, increasing the risk of PC carcinogenesis among 
male DM patients male smokers.79
Recent meta-analyses revealed an association between 
T2DM and cancer in Austria. The strongest relationship was 
demonstrated for liver and PC, followed by endometrial 
cancer. A study investigated cancer incidence in Tyrolean 
subjects with T2DM by linking the data from the DM and can-
cer registries, including 5,709 T2DM patients. Site-specific 
analyses revealed statistically significantly elevated SIRs for 
PC (1.78; 95% CI, 1.02-2.89) for women, and (1.87; 95% CI, 
1.11-2.96) for men. Sub-analyses performed by time of DM 
diagnosis revealed that SIR was highest in the first year after 
DM diagnosis, but the SIR was higher for cancers in women 
more than five years after DM diagnosis.80 
A study of the association between T2DM and the risk of 
PC adenocarcinoma in pooled data from the National Cancer 
Institute PC cohort consortium in USA included 1,621 pan-
creatic adenocarcinoma cases and 1,719 matched controls 
from 12 cohorts using a nested case-control study design. 
The results show that self-reported DM was associated with 
a 40% increased risk of PC (OR, 1.40; 95% CI, 1.07-1.84). The 
association differed by duration of DM. The risk was highest 
for those with a duration of two to eight years (OR, 1.79; 95% 
CI, 1.25-2.55). There was no association for those with nine 
and above years of DM (OR, 1.02; 95% CI, 0.68-1.52). The 
findings of the study provide support for a relationship be-
tween DM and PC risk. The absence of association in those 
with the longest duration of DM may reflect hypoinsulinemia 
and warrants further investigation.81 Metformin may have a 
protective effect on the development of PC.15
A hospital-based case-control study at University of Texas 
M. D. Anderson Cancer Center, USA was conducted from 
2004 to 2008 enrolling 973 patients with pancreatic ad-
enocarcinoma, including 259 DM and 863 controls, 109 of 
whom were diabetics. DM patients who had taken metformin 
had a significantly lower risk of PC compared to those who 
had not taken metformin, with adjustments for potential con-
founders. This difference remained statistically significant 
when the analysis was restricted to patients with a duration 
of diabetes over two years or those who never used insulin. 
In contrast, diabetic patients who had taken insulin or insulin 
secretagogues had a significantly higher risk of PC compared 
to DM patients who had not taken these drugs.12
A meta-analysis of 9,220 individuals with PC in 36 studies 
published between 1966 to 2005 included 17 case-control 
and 19 cohort studies. The combined summary OR was 1.82, 
95% CI 1.66-1.89, with evidence of heterogeneity across the 
studies (p<0.002 for case control and p<0.05 for cohort 
studies) that was explained, in part, by higher risks being re-
ported by smaller studies.16 
The complex relationship between the diseases has been 
the subject of numerous clinical, epidemiological, and ex-
perimental studies. Epidemiologic studies have suggested 
that long-standing T2DM is a modest risk factor for the devel-
opment of PC. Meta-analysis of multiple cohort and case con-
trol studies shows that the risk of PC in patients who have had 
DM for more than 5 years is 1.5- to 2-fold higher than recently 
diagnosed DM cases.82 In a recent meta-analysis of 20 pub-
lications, comprising 13,008 cancer patients with con-
current T2DM, researchers found that patients treated with 
metformin had better overall and cancer-specific survival 
than those treated with other types of glucose lowering 
agents.83 A meta-analysis of three studies, in which 2,192 PC 
patients were compared with 5,113 controls, revealed a 
1.8-fold increase in risk of PC associated with T2DM.84
A population-based retrospective cohort study from 
British Columbia, Canada linked health databases found a 
significantly increased risk of PC within three months follow-
ing DM onset.85 Another study showed an increased risk of de-
veloping PC in patients with T2DM among randomly selected 
patients in the San Francisco Bay Area.86 Finally, a cohort 
study in USA comparing 110,919 DM subjects and 211,695 
controls provides strong support for an etiological role of 
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T2DM and hyperinsulinemia in the pathogenesis of PC.87
4. Association between duration of type 2 diabetes 
mellitus and the risk of pancreatic cancer
The development of DM within a few years of a PC diag-
nosis suggests an effect of the tumor, whereas DM of longer 
duration is more likely to contribute to the development of 
PC.14 In many studies, an association between long-standing 
DM and an increased rate of death from PC was observed. 
Controversies also exist regarding the association of 
long-standing DM and PC; some epidemiological studies re-
fute the possibility that long-standing DM is a risk factor for 
PC.88-90 However, a similar study in the USA reported that 
long-standing DM increases the risk of PC by 40% to 100%.84 
Moreover, a review of studies examining the association be-
tween T2DM and PC suggests that long-standing DM is an 
etiologic factor for PC; new onset is its manifestation. There 
is a modestly elevated risk of PC among persons with 
long-standing DM.83 
In contrast, recent onset T2DM is associated with a four to 
seven-fold increase in risk of PC, such that 1% to 2% of pa-
tients with recent onset DM will develop PC within three 
years.91 Using data from the General Practice Research 
Database, a study in 2012 showed that DM was associated 
with an increased risk of PC but the risk is to newly diagnosed 
DM of less than two years.92 DM individuals who had been di-
agnosed less than four years prior had a 50% greater risk of 
developing malignancy compared with individuals who had 
DM for over four years. These results support a strong causal 
association between recent T2DM and PC.16,77 This is in con-
trast to other findings that long-standing DM has higher risk 
of developing PC than short-term T2DM.
CONCLUSION
This review finds that T2DM and PC are common health 
problems, and an association between these diseases was 
demonstrated by several epidemiological studies. The rela-
tionships between PC and alterations in glucose metabolism 
are very complex. In many studies, an association between 
long-standing T2DM and an increased rate of subsequent 
death from PC was indicated, but controversies exist. Some 
epidemiological studies have excluded the possibility that 
long-standing DM is a risk factor for PC; rather recent onset 
contributed more to carcinogenesis. Some studies showed 
evidence that longstanding diabetes is an etiologic factor for 
PC, while new onset diabetes is its manifestation, but still 
there is discrepancy in the literature. The main finding of this 
review were that metformin has a protective effect on the de-
velopment of PC and long term duration of DM was not a risk 
factor for PC. Most research reported that recent-onset dia-
betes was associated with increased risk for PC. In con-
clusion, it is believed that T2DM, duration of diabetes are risk 
factor for pancreatic carcinogenesis and there is metabolic 
link between the diseases. 
RECOMMENDATION
In summary, the finding of the review recommends early 
detection and screening of new onset T2DM patient for PC 
should be employed in the management of patients with 
T2DM. Understanding the mechanisms of the relationship 
between DM and PC is important for improving long-term sur-
vival, and opens research opportunities for the development 
of novel preventive and therapeutic strategies. In addition, 
future studies should focus on understanding the patho-
genesis of T2DM-associated PC and identifying biomarkers 
that can distinguish whether the cancer is T2DM associated 
or any other causes of PC carcinogenesis.
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